Pfizer has ramped up its efforts to “outdo cancer” since it acquired oncology biotech firm Seagen for $43 billion in December. The acquisition doubled its cancer drug pipeline to 60 different experimental programs, CNBC reported. Analysts have advised that it will take a few years for some of the company’s cancer drugs that are currently in mid-stage decelopment to show pivotal clinical trial data.